NK Cell Therapy: The Immune System's
First Line of Defense, Amplified.

NK (Natural Killer) cell therapy uses a type of white blood cell that is part of the innate immune system. Unlike T-cells, NK cells can recognize and kill cancer cells without prior sensitization or HLA matching. They use a balance of activating and inhibitory receptors to detect stressed or malignant cells. In therapy, NK cells are either collected from the patient (autologous) or from healthy donors (allogeneic), expanded in the lab with cytokines like IL-2, IL-15, or IL-21, and reinfused to boost anti-cancer immunity.

As of June 2026, no NK cell therapy has received full FDA approval for cancer treatment. However, several products are in advanced clinical trials: FT516 (Fate Therapeutics) in AML, FT596 (CAR-NK) in B-cell malignancies, and PNK-007 in various hematologic cancers. In China, NK cell therapy is offered under NMPA medical technology frameworks, primarily in clinical research or adjunctive settings. It is widely used in China, Japan, South Korea, and Southeast Asia.

Response rates vary by indication and setting. In hematologic malignancies (AML, ALL, lymphoma), NK cell therapy shows ORR of 35-50% in clinical studies. As adjuvant therapy post-transplant or post-surgery, some studies report improved disease-free survival. In solid tumors, results are more modest and NK therapy is typically used in combination with other modalities. Evidence is promising but less mature than CAR-T, and large Phase 3 data are still pending.

Costs vary significantly by country and product type. In India, autologous NK therapy ranges from $20,000-$40,000. In China, $30,000-$50,000. In Thailand and Turkey, $35,000-$60,000. Allogeneic off-the-shelf products (e.g., FT516 in trials) are priced higher. In the USA and Germany, NK therapy is mostly available through clinical trials at no direct cost to eligible patients. These prices reflect self-pay international patient pricing.

NK cell therapy has several distinct advantages: (1) Off-the-shelf availability — allogeneic NK products can be administered immediately without waiting for manufacturing; (2) No HLA matching required — unlike T-cell therapies; (3) Much lower risk of cytokine release syndrome (CRS) — typically mild, Grade 1-2; (4) No ICANS (neurotoxicity) reported in major series; (5) No graft-versus-host disease (GvHD) risk with allogeneic NK — unlike donor T-cells. The trade-off is generally lower potency and shorter in vivo persistence compared to CAR-T.

NK cell therapy has broader eligibility than CAR-T. Candidates include: patients with hematologic malignancies (AML, ALL, lymphoma, myeloma) as consolidation or post-transplant; solid tumor patients in adjuvant setting post-surgery/chemotherapy; patients who cannot tolerate intensive therapies due to age or comorbidities; ECOG 0-2 generally. Contraindications are minimal — mainly uncontrolled active infection or severe organ failure.

NK cell therapy is among the best-tolerated cellular therapies. Common side effects are mild: transient fever and chills during infusion (Grade 1-2 in ~20% of patients), fatigue for 24-48 hours, and occasional mild nausea. Severe CRS is rare (<5%). ICANS has not been reported in major series. Allogeneic NK does not cause GvHD. Most patients receive treatment as outpatient or with only brief observation.

Timeline depends on product type. Off-the-shelf allogeneic NK products can be scheduled within 1-2 weeks of case approval. Autologous NK (from patient's blood) requires 2-3 weeks for collection and expansion. Treatment is often given in multiple infusions (typically 3-6 doses over 2-6 weeks). Each infusion takes 30-60 minutes with 2-4 hours observation. Total treatment course is usually 2-4 weeks.